Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM |
|||
YLA0711MO-48T | Shanghai YL Biotech | 48T | EUR 465 |
Human IgG antibody Laboratories manufactures the m spike igm spep reagents distributed by Genprice. The M Spike Igm Spep reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike IgM. Other M products are available in stock. Specificity: M Category: Spike Group: Igm Spep
Human Cytomegalovirus IgG / IgM, Toxoplasma IgG / IgM, Rubella IgG Rapid Test Kit |
||
Abbexa | 20 tests | EUR 410.4 |
Human IgA, IgG and IgM AssayLite Multiplex Fluorescent Immunoassay Kit |
||
AssayPro | 96 Well Plate | EUR 1472.4 |
Mouse Phosphatidylinositol antibody IgG/IgM (PI Ab IgG/IgM) CLIA Kit |
||
Abbexa | 96 tests | EUR 990 |
Mouse phosphatidylinositol antibody IgG/IgM (PI Ab IgG/IgM) ELISA Kit |
||
Abbexa | 96 tests | EUR 904.8 |
Rat Phosphatidylinositol Antibody IgG/IgM (PI Ab IgG/IgM) ELISA Kit |
||
Abbexa | 96 tests | EUR 943.2 |
Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit |
||
ChemNorm | 96T | EUR 586.8 |
Mouse phosphatidylinositol antibody IgG/IgM,PI Ab-IgG/IgM ELISA Kit |
||
ChemNorm | 48T | EUR 405.6 |
SARS (IN1) Spike Peptide |
|||
3221P | ProSci | 0.05 mg | EUR 197.7 |
Description: (IN) SARS (IN1) Spike peptide |
SARS (IN2) Spike Peptide |
|||
3223P | ProSci | 0.05 mg | EUR 197.7 |
Description: (IN) SARS (IN2) Spike peptide |
SARS (IN3) Spike Peptide |
|||
3225P | ProSci | 0.05 mg | EUR 197.7 |
Description: (IN) SARS (IN3) Spike peptide |
91 SOW Surrogate Spike |
|||
CLPP-S91 | Scientific Laboratory Supplies | 2ML | EUR 247.2 |
EPH Surrogate Spike Mix |
|||
NJDEP-EPH-SS | Scientific Laboratory Supplies | 1ML | EUR 242.4 |
Mouse Monoclonal Anti-Porcine epidemic diarrhea virus Spike protein S1 (PEDV-S1) IgM, unlabeled |
|||
PEDV13-M | Alpha Diagnostics | 100 ul | EUR 578.4 |
SARS-CoV Spike Protein |
|||
abx060655-1mg | Abbexa | 1 mg | EUR 2030.4 |
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
MS Soil Spike Std 2 |
|||
SOILSPS01 | Scientific Laboratory Supplies | 1L | EUR 1686.84 |
Base/Neutrals Matrix Spike |
|||
CLPS-MSB | Scientific Laboratory Supplies | 1ML | EUR 44.4 |